PPARD and obesity due to melanocortin 4 receptor deficiency: PPARδ agonists have been shown beneficial in models of metabolic disorders in primates and may thus possess therapeutic potential in hyperlipidemia, atherosclerosis, obesity, and diabetes [93,94].